Insight Molecular Diagnostics (LTS:0KCC) Total Payout Ratio: (As of Sep. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0KCC Insight Molecular Diagnostics Inc LTS:0KCC
45 GF Score
Price $4.01
GF Value $1.10
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Insight Molecular Diagnostics Total Payout Ratio?

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

Insight Molecular Diagnostics's current Total Payout Ratio is .

Insight Molecular Diagnostics Total Payout Ratio Related Terms

Insight Molecular Diagnostics Total Payout Ratio Historical Data

* Premium members only.

The historical data trend for Insight Molecular Diagnostics's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Insight Molecular Diagnostics Total Payout Ratio Chart

Insight Molecular Diagnostics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Payout Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Insight Molecular Diagnostics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

LTS:0KCC vs QUCY, BNR, XGN: Total Payout Ratio Comparison

For the Diagnostics & Research subindustry, Insight Molecular Diagnostics's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Insight Molecular Diagnostics Total Payout Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Insight Molecular Diagnostics's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where Insight Molecular Diagnostics's Total Payout Ratio falls into.


LTS:0KCC
45GF Score
Insight Molecular Diagnostics Inc LTS:0KCC
Total Payout Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Insight Molecular Diagnostics Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

Insight Molecular Diagnostics's Total Payout Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (-0 + 28.656 + -0) / -50.222
=0.57

Insight Molecular Diagnostics's Total Payout Ratio for the quarter that ended in Jun. 2026 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (-0 + -0.175 + -0) / -11.26
=-0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Is Insight Molecular Diagnostics (LTS:0KCC) Overvalued in 2026?

Based on GuruFocus' analysis, Insight Molecular Diagnostics stock appears to be overvalued. The current stock price of $4.01 is trading 264.5% above its estimated GF Value™ of $1.10. GuruFocus considers Insight Molecular Diagnostics to be Significantly Overvalued.

Key valuation signals for LTS:0KCC:

  • Total Payout Ratio:
  • GF Value™: $1.10 vs. price of $4.01 (264.5% above fair value)
  • GF Score™: 45/100 with 7 warning signs

No single metric tells the full story. See the LTS:0KCC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Insight Molecular Diagnostics Business Description

Other Exchanges IMDX:USA7OC0:Germany
Address 2 International Plaza Drive, Suite 510, Nashville, TN, USA, 37217
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.
45GF Score

Get the complete analysis for LTS:0KCC

Total Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.01
Price
$1.10
GF Value